Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ROIV Stock 12 Month Forecast
Average Price Target
$20.31
▲(33.88% Upside)
| Highest Price Target$24.00 | Average Price Target$20.31 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$16.5
Hold
8.77%
Upside
Reiterated
09/24/25
Leerink Partners
$18→$22
Buy
45.02%
Upside
Reiterated
09/19/25
TD Cowen
$23
Buy
51.62%
Upside
Reiterated
09/18/25
H.C. Wainwright
$18→$20
Buy
31.84%
Upside
Reiterated
09/18/25
J.P. Morgan
$16→$20
Buy
31.84%
Upside
Reiterated
09/18/25
Guggenheim
$15→$21
Buy
38.43%
Upside
Reiterated
09/17/25
Goldman Sachs
$20→$24
Buy
58.21%
Upside
Reiterated
09/17/25
Citi
$16
Buy
5.47%
Upside
Initiated
09/03/25
Positive Outlook for Roivant Sciences Driven by Brepocitinib's Phase 3 Potential and Undervalued StockWe believe the breadth of IST/case studies in the literature are supportive of an efficacy signal for JAK1 inhibition in DM, although we acknowledge the lack of Ph2 proof-of- concept data for brepocitinib adds risk to the readout. The dual targeting of JAK1 and TYK2 could build upon JAK1 inhibition alone. Further, blinded steroid taper data suggests strong clinical execution that could mitigate an outsized placebo response. Ahead of the data, we believe ROIV’s current valuation is pricing in minimal value attributed for brepocitinib, and we see potential for upside on a positive DM readout, which could potentially liberate ROIV shares from the range-bound trading pattern the stock has endured over the last ~1-2 years. Initiate Buy/High Risk, TP $16/shr.
Cantor Fitzgerald
―
Buy
―
Reiterated
06/18/25
Jefferies
$18
Buy
18.66%
Upside
Reiterated
03/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$16.5
Hold
8.77%
Upside
Reiterated
09/24/25
Leerink Partners
$18→$22
Buy
45.02%
Upside
Reiterated
09/19/25
TD Cowen
$23
Buy
51.62%
Upside
Reiterated
09/18/25
H.C. Wainwright
$18→$20
Buy
31.84%
Upside
Reiterated
09/18/25
J.P. Morgan
$16→$20
Buy
31.84%
Upside
Reiterated
09/18/25
Guggenheim
$15→$21
Buy
38.43%
Upside
Reiterated
09/17/25
Goldman Sachs
$20→$24
Buy
58.21%
Upside
Reiterated
09/17/25
Citi
$16
Buy
5.47%
Upside
Initiated
09/03/25
Positive Outlook for Roivant Sciences Driven by Brepocitinib's Phase 3 Potential and Undervalued StockWe believe the breadth of IST/case studies in the literature are supportive of an efficacy signal for JAK1 inhibition in DM, although we acknowledge the lack of Ph2 proof-of- concept data for brepocitinib adds risk to the readout. The dual targeting of JAK1 and TYK2 could build upon JAK1 inhibition alone. Further, blinded steroid taper data suggests strong clinical execution that could mitigate an outsized placebo response. Ahead of the data, we believe ROIV’s current valuation is pricing in minimal value attributed for brepocitinib, and we see potential for upside on a positive DM readout, which could potentially liberate ROIV shares from the range-bound trading pattern the stock has endured over the last ~1-2 years. Initiate Buy/High Risk, TP $16/shr.
Cantor Fitzgerald
―
Buy
―
Reiterated
06/18/25
Jefferies
$18
Buy
18.66%
Upside
Reiterated
03/11/25
Best Analysts Covering Roivant Sciences
1 Month
xxx
Success Rate
10/16 ratings generated profit
Average Return
+4.39%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +4.39% per trade.
3 Months
xxx
Success Rate
16/24 ratings generated profit
Average Return
+17.00%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.00% per trade.
1 Year
Success Rate
30/34 ratings generated profit
Average Return
+42.59%
reiterated a buy rating 9 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +42.59% per trade.
2 Years
xxx
Success Rate
16/16 ratings generated profit
Average Return
+32.01%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ROIV Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
4
4
4
4
5
Buy
7
12
11
10
11
Hold
4
5
7
11
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
21
22
25
28
Each month's total comprises the sum of three months' worth of ratings.
ROIV Financial Forecast
ROIV Stock Forecast FAQ
What is ROIV’s average 12-month price target, according to analysts?
Based on analyst ratings, Roivant Sciences’s 12-month average price target is 20.31.
What is ROIV’s upside potential, based on the analysts’ average price target?
Roivant Sciences has 33.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ROIV a Buy, Sell or Hold?
Roivant Sciences has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Roivant Sciences’s price target?
The average price target for Roivant Sciences is 20.31. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $16.00. The average price target represents 33.88% Increase from the current price of $15.17.
The highest analyst price target is $24.00 ,the lowest forecast is $16.00. The average price target represents 33.88% Increase from the current price of $15.17.
What do analysts say about Roivant Sciences?
Roivant Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ROIV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.